- Home
- CORT vs TVTX Comparison
CORT vs TVTX Comparison
Compare CORT & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CORT | TVTX |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.3B |
| IPO Year | 2001 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CORT | TVTX |
|---|---|---|
| Price | $34.12 | $27.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $105.20 | $36.25 |
| AVG Volume (30 Days) | ★ 1.7M | 1.3M |
| Earning Date | 05-25-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $761,407,000.00 | N/A |
| Revenue This Year | $29.97 | $44.62 |
| Revenue Next Year | $30.25 | $32.09 |
| P/E Ratio | $41.57 | ★ N/A |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $28.66 | $12.91 |
| 52 Week High | $117.33 | $42.13 |
Technical Indicators
Market Signals| Indicator | CORT | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.22 | 36.30 |
| Support Level | $33.53 | $27.01 |
| Resistance Level | $41.92 | $31.47 |
| Average True Range (ATR) | 2.46 | 1.42 |
| MACD | 0.27 | -0.15 |
| Stochastic Oscillator | 45.15 | 13.74 |
Price Performance
Historical ComparisonAbout CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.